[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369046-105":59,"doc-detail-369046-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","multimodal-spectrum-of-approach-in-poorly-differentiated-thyroid-carcinoma-an-updated-analysis","Multimodal spectrum of approach in poorly differentiated thyroid carcinoma - an updated analysis","","Thyroid malignancy is the most common endocrine cancer worldwide, with rising detection among younger adults and most cases belonging to non-medullary types. Poorly differentiated thyroid carcinoma, representing 1% to 5% of thyroid malignancies, remains less understood and shows diverse histological patterns that complicate routine diagnosis. The study provides an updated multimodal framework, integrating emergent biomarkers and molecular-genetic profiles as prognostic markers and guides for anti-cancer therapy, while noting persistently severe prognosis despite recent advances.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/multimodal-spectrum-of-approach-in-poorly-differentiated-thyroid-carcinoma-an-updated-analysis/369046/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/multimodal-spectrum-of-approach-in-poorly-differentiated-thyroid-carcinoma-an-updated-analysis/369046.png","ImageObject",300,407,{"name":92,"@type":93},"acoobca","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the focus of this updated analysis of poorly differentiated thyroid carcinoma?","Question",{"text":113,"@type":114},"It summarizes an updated multimodal approach to poorly differentiated thyroid carcinoma, including emergent biomarkers and molecular-genetic constellation for diagnosis and prognosis.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which biomarkers and molecular alterations are highlighted as prognostic markers?",{"text":118,"@type":114},"The text emphasizes molecular and genetic profiles involving RAS, TERT, BRAF, TP53, PTEN, copy number alterations, and PIK3CA, and notes biomarkers that might be detected via cytology or blood assays such as cfDNA.",{"name":120,"@type":111,"acceptedAnswer":121},"How does the article describe treatment planning for this cancer?",{"text":122,"@type":114},"It outlines a multilayered therapeutic strategy combining traditional management (surgery, radioiodine ablation, TSH-suppressive levothyroxine with lifelong thyroglobulin surveillance) with novel therapies such as multi-kinase inhibitors.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},369046,1790217107,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":41,"preview_page_count":19,"preview_urls":146},3985747870733,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","REVIEW  \nR J M E  \nRomanian Journal of Morphology & Embryology  \n[http://www.rjme.ro/](http://www.rjme.ro/)  \nMultimodal spectrum of approach in poorly differentiated thyroid carcinoma (an updated analysis)  \nMIHAI COSTACHESCU1–3), NINA IONOVICI4), DANA CRISTINA TERZEA5,6), FLORINA VASILESCU6,7), LUCIAN-GEORGE EFTIMIE7), ALEXANDRA-IOANA TRANDAFIR8), ANA-MARIA GHEORGHE8), OANA-CLAUDIA SIMA8), CLAUDIU NISTOR3,9), MARA CARSOTE8,10)  \n1) Doctoral School, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania  \n2) Department of Radiology and Medical Imaging, Dr. Carol Davila Central Military Emergency University Hospital, Bucharest, Romania  \n3) Department of Thoracic Surgery, Dr. Carol Davila Central Military Emergency University Hospital, Bucharest, Romania  \n4) Department of Occupational Medicine, University of Medicine and Pharmacy of Craiova, Romania  \n5) Department of Pathology, C. I. Parhon National Institute of Endocrinology, Bucharest, Romania  \n6) Oncoteam Diagnostics, Bucharest, Romania  \n7) Department of Pathology, Dr. Carol Davila Central Military Emergency University Hospital, Bucharest, Romania  \n8) Department of Clinical Endocrinology V, C. I. Parhon National Institute of Endocrinology, Bucharest, Romania  \n9) Discipline of Thoracic Surgery II, Department 4 – Cardio-Thoracic Pathology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania  \n10) Department of Endocrinology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania  \nAbstract  \nThyroid malignancy represents the most common type of endocrine cancer, with an increasing incidence all over the world, including an increasing rate of detection among younger adults, 90% to 95% of all cases being non-medullary types. Poorly differentiated thyroid cancer, accounting 1% to 5% of all thyroid malignancies, is a less understood neoplasm compared to the other more frequent and better described thyroid cancers, associating various histological patterns that might bring pitfalls of diagnosis in everyday practice. We aimed to provide an updated analysis in the field of poorly differentiated thyroid carcinoma, based on a multimodal approach, including emergent biomarkers. The current data offers a robust framework for elucidating the biology of poorly differenced thyroid malignancy and further on, it provides the basis for a multilayered therapeutic approach. Emergent biomarkers might be detected from cytological analysis based on fine-needle aspiration or blood assays as cell-free deoxyribonucleic acid (cfDNA), but the most important remains the identification of the molecular and genetic constellation in terms of analyzing RAS, telomerase reverse transcriptase (TERT), B-Raf proto-oncogene, serine/threonine kinase (BRAF), tumor protein p53 (TP53), phosphatase and tensin homolog (PTEN), copy number alterations (CNA) and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) profile, which serve as prognostic markers and pointers of anti-cancer medical therapy. Overall, despite recent advances in multimodal management, the prognostic remains severe. The issue is ongoing, and we expect a massive expansion within the following years, across a guideline-based, as well as a personalized decision.  \nKeywords: follicular, papillary, immunohistochemistry, thyroidectomy.  \n􀀕 Introduction  \nThyroid malignancy represents the most common typeof endocrine cancer with an increasing incidence all over the world, including an increasing rate of detection among younger adults, 90% to 95% of all cases being nonmedullary types [1–3]. Aggressive types have a low impact from an epidemiological perspective, but they carry an important disease burden due to a recurrent/persistent condition and a poor outcome. While many areas regarding the pathogenic mechanisms and prognostic markers are still a matter of debate, these malignancies have been recently re-classified to provide a new practical perspective amidst a multimodal appro","cbCaifi7IbuGUZs9","https://ap.wps.com/l/cbCaifi7IbuGUZs9","pdf",2084399,12,"English","# Abstract\n# Introduction","[{\"question\":\"What is the focus of this updated analysis of poorly differentiated thyroid carcinoma?\",\"answer\":\"It summarizes an updated multimodal approach to poorly differentiated thyroid carcinoma, including emergent biomarkers and molecular-genetic constellation for diagnosis and prognosis.\"},{\"question\":\"Which biomarkers and molecular alterations are highlighted as prognostic markers?\",\"answer\":\"The text emphasizes molecular and genetic profiles involving RAS, TERT, BRAF, TP53, PTEN, copy number alterations, and PIK3CA, and notes biomarkers that might be detected via cytology or blood assays such as cfDNA.\"},{\"question\":\"How does the article describe treatment planning for this cancer?\",\"answer\":\"It outlines a multilayered therapeutic strategy combining traditional management (surgery, radioiodine ablation, TSH-suppressive levothyroxine with lifelong thyroglobulin surveillance) with novel therapies such as multi-kinase inhibitors.\"}]","Multimodal spectrum of approach in poorly differentiated thyroid carcinoma - an updated analysis | PDF",1790180353,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9ecf15167f96f3a4f7b8c6f973f8ec7d.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8cd3d080ccc24e10020731b1f60e00e3.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c765601044df590bb9370cb8c319225d.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1ff577fee44dea1a51202fbd41bb6f55.webp",980,1385]